Originally spun out of Bristol-Myers Squibb, ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings... Show more
The Aroon Indicator for CNVVF entered a downward trend on August 15, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 76 similar instances where the Aroon Indicator formed such a pattern. In of the 76 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved above the 0 level on August 29, 2025. You may want to consider a long position or call options on CNVVF as a result. In of 25 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CNVVF just turned positive on September 03, 2025. Looking at past instances where CNVVF's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.761) is normal, around the industry mean (11.022). P/E Ratio (31.604) is within average values for comparable stocks, (59.569). Projected Growth (PEG Ratio) (1.690) is also within normal values, averaging (1.744). Dividend Yield (0.020) settles around the average of (0.016) among similar stocks. P/S Ratio (2.922) is also within normal values, averaging (12.728).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CNVVF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
IDNA | 23.00 | 0.43 | +1.91% |
iShares Genomics Immnlgy & Hlthcr ETF | |||
FNDC | 44.16 | 0.39 | +0.89% |
Schwab Fundamental International SmEqETF | |||
DDLS | 41.90 | 0.13 | +0.31% |
WisdomTree Dynamic Intl SmCap Eq ETF | |||
HYSD | 20.31 | 0.02 | +0.12% |
Columbia Short Duration High Yield ETF | |||
EPV | 25.56 | -0.26 | -1.00% |
ProShares UltraShort FTSE Europe |
A.I.dvisor indicates that over the last year, CNVVF has been loosely correlated with SERA. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if CNVVF jumps, then SERA could also see price increases.
Ticker / NAME | Correlation To CNVVF | 1D Price Change % | ||
---|---|---|---|---|
CNVVF | 100% | N/A | ||
SERA - CNVVF | 33% Loosely correlated | -2.05% | ||
TMCI - CNVVF | 27% Poorly correlated | N/A | ||
SAFLY - CNVVF | 26% Poorly correlated | N/A | ||
NMTC - CNVVF | 22% Poorly correlated | +8.47% | ||
STVN - CNVVF | 22% Poorly correlated | +4.82% | ||
More |
Ticker / NAME | Correlation To CNVVF | 1D Price Change % |
---|---|---|
CNVVF | 100% | N/A |
Pharmaceuticals category (387 stocks) | 10% Poorly correlated | +1.69% |
Pharmaceuticals: Other category (103 stocks) | -3% Poorly correlated | +0.58% |